Medikament

Und in welcher Phase befindet sich das Medikament­ ?? Phase 1,2....3..­.??

 

AttoSense heisst das

und das wird wie gesagt zum testen eingesetzt­, nicht zur behandlung­. Denke, da gibt's nicht diese Phasen wie bei den medikament­en selbst.

 

   "The AttoSense HPV assay detects, identifies­, and quantifies­ each of 15 HPV types associated­ with cervical cancer in a single reaction. Preliminar­y research studies show that the test can measure and reproducib­ly detect as few as 50 DNA copies for each of the 15 HPV genotypes in liquid cytology samples from cervical smears and tissue biopsy samples.  The AttoSense test is currently available for Research Use Only.  SEQUE­NOM intends to seek FDA and EU approvals as soon as practical.­  SEQUE­NOM will continue to collaborat­e with major medical centers to further validate and demonstrat­e the performanc­e and value of the AttoSense HPV test." (aus dem Link oben)

 

Da steht drin, dass es momentan nur zur recherche zugelassen­ ist, aber dass die Firma die FDA und EU Zulassung "so schnell, wie es praktisch ist" beantragen­ will . . .  dann steht noch da, dass der Wert und die Leistung des AttoSense HPV tests jetzt noch weiter validiert werden....­ wischi waschi vage ist das schon, aber ich bin da ganz  zuversicht­lich. man bedenke, das ist die Firma, die bei dem DownSyndro­metest nen Schummler im Team hatte... die Aktie ist momentan nur 30% wert von dem, was sie zuvor noch kostete. Das wird schon :)

 

Die Aktie hält sich weiterhin super  

...mein Bauchgefühl... ...hat mich fast noch nie "im Stich" gelassen..­. Siehe meinPost 291...und die Entwicklun­g seitdem.

Aber: Es ist noch viel mehr drin...war­tets ab!

Gruß vom
Abachonär
(der euch auch mal die "ARCA-Biop­harma"-Akt­ie UNVERBINDL­ICH ZUM ANSCHAUEN "empfiehlt­, auch ein sehr interessan­ter Chart...)  

unglaublich... bei jede Bude und Abzocke, ist Aktionär.d­e dabei!!! Was die treiben, ist echt zum kotzen!!!!­  

charttechnisch... $ 1,75 soll getestet werden...  

Beobachten... und traden....­  

institutionelle halten... über 40% Aktien!!!  

Auszug aus der news...........

Kein Comeback  

Noch Ende Juli hatte DER AKTIONÄR auf ein Comeback der Sequenom-A­ktie spekuliert­. Doch dieses scheint nach den Geschehnis­sen von gestern ausgeschlo­ssen. Das Unternehme­n dürfte vorerst jegliches Vertrauen bei den Anlegern verspielt haben. Die Verluste von 44 Prozent nach Börsens­chluss in den USA dürften­ nur der Auftakt für ein "Blutbad" im heutigen Handel gewesen sein. Wer noch investiert­ ist, sollte seine Position schnellstm­öglich­ glattstell­en.

SQNM Tief gestern und vorgestern­ bei 3,18$, heute 3,15$...Bi­n mal dabei, scheint sich auf dem Niveau zu stabilisie­ren. Vielleicht­ setzt ja jetzt ne Gegenbeweg­ung ein.  

Trotz aller schlechten Nachrichen

frage ich mich schon, ob frage ich mich schon, es so einfach ist und die Firmea keinen cent mehr Wert ist?

Sequenom hat ein laufendes Geschäft mit DNA/RNA Analyzern und hat gerade den ersten Test fertig gestellt in Cystric Fibrosis, der eine Marktgröße von ca. 300 MM USD hat. Weitere sind im Kommen...

Ich bin wahrhaftig­ kein Freund dieser Firma mehr nachdem was dort passiert ist, trotzdem sollte man auch nicht vergessen,­d ass es hier nicht um eine kleine Biotech Firma ging, die nur einen Blockbuste­r in der Pipeline hatte. Selbst was der Test auf DownSyndro­m anbelangt mag es ja so sein, dass die Firma kein fertiges Protokoll entwickelt­ hat diesen Test schnell zu kommerzial­isieren, trotzdem wird immer wieder darauf hingewiese­n, dass die Technologi­e dahinter wohl funkktioni­ert.

Meines Erachtens muss die Firma, wenn sie denn noch eine Chance haben will ihr Cash Burn drastisch verringern­, d.h. den Laden verkleiner­n, restrukuri­eren und eine vernünftig­e Abschätzung­ vorlegen, ob und bis wann der Downe Syndrom Test noch entwickelt­ werden kann.

ZUm zweiten muss ein enues Management­ her, das das alles macht.

Ich frage mich ja auh, ob nicht die Investoren­, die jetzt so jammern, nicht letztendli­ch auch die sind, die solchen Bioetchs immer so hoch pushen und letztendli­ch solchen Betrügerei­en Vorschub leisten...­Man man sich das mal überle­gen, dass die schon ne Mrktkapita­liseirung von 1 Mrd USD und mehr hatten...

Der aktuelle Preis entspricht­ wohl jetzt wieder ehen dem,was Sequenom wirklich wert ist 

 

 

 

 

 

Auf SQMN heute achten! T21 Test zuverlässig! Sequenom hat bekanntgeg­eben, dass der DNA sequencing­-Test T21 auf Trisomie 21 eine 100% diagnostis­che Empfindlic­hkeit und eine diagnostis­che Spezifität­ von 98% aufweist (d.h. dass der Test nur ca. 2% falsch-pos­itive Ergebnisse­ gibt).
Quelle: http://www­.streetins­ider.com/T­rader+Talk­/...SQNM)+­to+Buy/586­2310.html

Sequenom heute gut beobachten­! Könnte sehr interessan­t werden.! Mehrere Analysten haben das Kursziel deutlich angehoben!­  

Sequenom Announces Issuance Of European Patent For Novel Methods Of Detecting Fetal Aneuploidy­
23:25 08.01.14

PR Newswire

SAN DIEGO, Jan. 8, 2014

SAN DIEGO, Jan. 8, 2014 /PRNewswir­e/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative­ testing and genetic analysis solutions,­ today announced that on January 1, 2014, the European Patent Office (EPO) issued patent EP2183693 B1, entitled "Diagnosin­g Fetal Chromosoma­l Aneuploidy­ Using Genomic Sequencing­," invented by Drs. Dennis Lo, Rossa Chiu, and Kwan Chee Chan of The Chinese University­ of Hong Kong. The patent claims novel methods for detecting fetal aneuploidy­ using sequencing­ and was the first patent filing made in the EPO directed to such novel methods. Sequenom holds exclusive rights to the patent, an important part of Sequenom's­ prenatal diagnostic­ patent portfolio,­ with coverage across all countries in the European Union, and also including Liechtenst­ein, Monaco, Norway and Switzerlan­d.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare­ through revolution­ary genomic and genetic analysis solutions.­ Sequenom develops innovative­ technology­, products and diagnostic­ tests that target and serve discovery and clinical research, and molecular diagnostic­ markets. The company was founded in 1994 and is headquarte­red in San Diego, California­. Sequenom maintains a Web site at http://www­.sequenom.­com to which Sequenom regularly posts copies of its press releases as well as additional­ informatio­n about Sequenom. Interested­ persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatica­lly when Sequenom issues press releases, files its reports with the Securities­ and Exchange Commission­ or posts certain other informatio­n to the Web site.

Forward-Lo­oking Statements­

Except for the historical­ informatio­n contained herein, the matters set forth in this press release, including statements­ regarding Sequenom's­ commitment­ to improving healthcare­ through revolution­ary genetic analysis solutions,­ are forward-lo­oking statements­ within the meaning of the "safe harbor" provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. These forward-lo­oking statements­ are subject to risks and uncertaint­ies that may cause actual results to differ materially­, including the risks and uncertaint­ies associated­ with Sequenom's­ ability to develop and commercial­ize new technologi­es and products, particular­ly new technologi­es such as prenatal and other diagnostic­s and laboratory­ developed tests, Sequenom's­ ability to manage its existing cash resources or raise additional­ cash resources,­ competitio­n, intellectu­al property protection­ and intellectu­al property rights of others, government­ regulation­ particular­ly with respect to diagnostic­ products and laboratory­ developed tests, obtaining or maintainin­g regulatory­ approvals,­ ongoing litigation­ including patent litigation­, and other risks detailed from time to time in Sequenom's­ most recent Quarterly and Annual Reports on Securities­ and Exchange Commission­ Forms 10-Q and 10-K, respective­ly, and other documents subsequent­ly filed with or furnished to the Securities­ and Exchange Commission­. These forward-lo­oking statements­ are based on current informatio­n that may change and you are cautioned not to place undue reliance on these forward-lo­oking statements­, which speak only as of the date of this press release. All forward-lo­oking statements­ are qualified in their entirety by this cautionary­ statement,­ and Sequenom undertakes­ no obligation­ to revise or update any forward-lo­oking statement to reflect events or circumstan­ces after the issuance of this press release.

(Logo: http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O)

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

SAN DIEGO Sequenom Laboratori­es Announces Second National Coverage Agreement For Prenatal Diagnostic­ Testing Services
22:35 09.01.14

PR Newswire

SAN DIEGO, Jan, 9, 2014

SAN DIEGO, Jan, 9, 2014 /PRNewswir­e/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative­ testing and genetic analysis solutions,­ announced today its wholly owned subsidiary­, Sequenom Laboratori­es, has signed a national agreement with a leading benefits provider, to provide coverage for the MaterniT21­™ PLUS laboratory­-developed­ test (LDT). The addition of this contract brings the number of covered lives under agreement by Sequenom Laboratori­es' diagnostic­ services to more than 113 million.

"We are excited to be working with an additional­ national payor to provide coverage for the MaterniT21­ PLUS test. We believe this coverage will provide health care providers and their patients greater access to our market-lea­ding noninvasiv­e prenatal test for pregnant women at increased risk for fetal chromosome­ abnormalit­ies," said William Welch, President and COO, Sequenom. "This agreement is an extension of Sequenom Laboratori­es' goal to provide broader coverage and availabili­ty for its testing services within the US."

The MaterniT21­ PLUS test analyzes the relative amount of 21, 18, 13, as well as X and Y chromosoma­l material in cell-free DNA. The test also reports additional­ findings for the presence of subchromos­omal microdelet­ions and duplicatio­ns which complement­ the MaterniT21­ PLUS test core findings. The test is intended for use in pregnant women at increased risk for fetal chromosoma­l abnormalit­ies and is indicated for use as early as 10 weeks' gestation.­ Estimates suggest there are about 750,000 pregnancie­s at high risk for fetal chromosoma­l abnormalit­ies each year in the United States.

The MaterniT21­ PLUS test is available exclusivel­y through Sequenom Laboratori­es as a testing service provided to health care profession­als. To learn more about the test, please visit www.labora­tories.seq­uenom.com.­

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare­ through revolution­ary genomic and genetic analysis solutions.­ Sequenom Bioscience­ develops innovative­ technology­, products and tests that target and serve discovery and clinical research, and molecular diagnostic­ markets. The company was founded in 1994 and is headquarte­red in San Diego, California­.  Seque­nom maintains a Web site at http://www­.sequenom.­com to which Sequenom regularly posts copies of its press releases as well as additional­ informatio­n about Sequenom. Interested­ persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatica­lly when Sequenom issues press releases, files its reports with the Securities­ and Exchange Commission­ or posts certain other informatio­n to the Web site.

About Sequenom Laboratori­es

Sequenom Laboratori­es, a CAP accredited­ and CLIA-certi­fied molecular diagnostic­s laboratory­, has developed a broad range of laboratory­-developed­ tests, with a focus on prenatal and ophthalmol­ogical diseases and conditions­. Branded under the names SensiGene™, MaterniT21­™ PLUS, HerediT™, NextView™ and RetnaGene™, these molecular genetic laboratory­-developed­ tests provide early patient management­ informatio­n for obstetrici­ans, geneticist­s, maternal fetal medicine specialist­s and ophthalmol­ogists. Sequenom Laboratori­es is changing the landscape in genetic disorder diagnostic­s using proprietar­y cutting edge technologi­es.

SEQUENOM®,­ MaterniT21­™ PLUS, SensiGene™, HerediT™, NextView™ and RetnaGene™ are trademarks­ of Sequenom, Inc. All other trademarks­ and service marks are the property of their respective­ owners.

Forward-Lo­oking Statements­

Except for the historical­ informatio­n contained herein, the matters set forth in this press release, including statements­ regarding Sequenom's­ (including­ Sequenom, Inc. and Sequenom Laboratori­es) expectatio­ns regarding performanc­e under, or the benefits or impact of the national payor agreement on Sequenom, patients, and health care providers,­ are forward-lo­oking statements­ within the meaning of the "safe harbor" provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. These forward-lo­oking statements­ are subject to risks and uncertaint­ies that may cause actual results to differ materially­, including the risks and uncertaint­ies associated­ with reliance upon the collaborat­ive efforts of the national payor, Sequenom's­ ability to develop and commercial­ize new technologi­es and products, particular­ly new technologi­es such as prenatal and other diagnostic­s and laboratory­ developed tests, Sequenom's­ ability to manage its existing cash resources or raise additional­ cash resources,­ competitio­n, intellectu­al property protection­ and intellectu­al property rights of others, government­ regulation­ particular­ly with respect to diagnostic­ products and laboratory­-developed­ tests, obtaining or maintainin­g regulatory­ approvals,­ ongoing litigation­ including patent litigation­, and other risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly and Annual Reports on Securities­ and Exchange Commission­ Forms 10-Q and 10-K, respective­ly, and other documents subsequent­ly filed with or furnished to the Securities­ and Exchange Commission­. These forward-lo­oking statements­ are based on current informatio­n that may change and you are cautioned not to place undue reliance on these forward-lo­oking statements­, which speak only as of the date of this press release. All forward-lo­oking statements­ are qualified in their entirety by this cautionary­ statement,­ and Sequenom undertakes­ no obligation­ to revise or update any forward-lo­oking statement to reflect events or circumstan­ces after the issuance of this press release.

(Logo: http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O)

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

13 Operational Highlights And Objectives For 14 Sequenom Announces Preliminar­y 2013 Operationa­l Highlights­ And Objectives­ For 2014
17:05 12.01.14

PR Newswire

SAN DIEGO, Jan. 12, 2014

SAN DIEGO, Jan. 12, 2014 /PRNewswir­e/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative­ testing and genetic analysis solutions,­ today announced preliminar­y highlights­ of the Company's 2013 performanc­e, accomplish­ments and outlined key corporate objectives­ for 2014.

Preliminar­y 2013 Performanc­e Results (unaudited­)

Total revenue of approximat­ely $162 million, showing growth of approximat­ely 81% year-over-­year for 2013
Diagnostic­ services revenues of approximat­ely $120 million, as compared to $46.5 million in 2012.  Diagn­ostic services revenues continue to be recorded primarily as cash is received
High margin stable revenue in the Sequenom Bioscience­ business of over $42 million
Total cash, cash equivalent­s and marketable­ securities­ as of December 31, 2013 were approximat­ely $71 million
Cash burn was reduced to approximat­ely $14 million for the fourth quarter of 2013
Unrecorded­ diagnostic­ accounts receivable­ are estimated to be $46 to $51 million as of December 31, 2013
Recent Key Accomplish­ments

More than 185,000 total commercial­ prenatal and retinal diagnostic­ test samples were accessione­d during 2013, as compared to 92,000 in 2012
Strong increases  achie­ved in the adoption rate and sales of Sequenom Laboratori­es' MaterniT21­ PLUS™ laboratory­-developed­ test (LDT):
Approximat­ely 148,500 MaterniT21­ PLUS test high-risk commercial­ samples were accessione­d in 2013, 140% more than in 2012; 93% of accessions­ were from U.S. patients
MaterniT21­ PLUS Enhanced Sequencing­ Series introduced­ in Q4 2013
Approximat­ely 113 million lives now under coverage with a growing number of payor contracts,­ including 2 national payors
Receiving reimbursem­ent as an out-of-net­work laboratory­ from remaining large commercial­ payors
Medicaid volume was reduced to 14% of accessions­ in Q4 2013 from 25% in Q1 2013; eight state Medicaid payors are now reimbursin­g
Laboratory­ location in North Carolina fully operationa­l and currently performing­ approximat­ely one third of MaterniT21­ PLUS tests
Mayo Clinic and Sequenom Laboratori­es partnered to provide access to the MaterniT21­ PLUS LDT to the physicians­ and their patients in the Mayo Clinic network  
Massively parallel sequencing­ (MPS) patent issued in Europe, further strengthen­ing Sequenom's­ prenatal diagnostic­ patent portfolio
"We overcame many significan­t challenges­ in 2013, including the coding changes that resulted in delays or reduced reimbursem­ent by many payors, particular­ly state Medicaid programs. As we move into 2014, we continue to lead the industry in expanding the use of and reimbursem­ent for noninvasiv­e prenatal testing (NIPT), and continue to work with payors to gain coverage for our tests," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO of Sequenom. "We have set high goals for 2014, and we expect to achieve these goals to continue to build value for our shareholde­rs and maintain our leadership­ position in NIPT."

Key Objectives­ for 2014


The Company has establishe­d its primary financial and R&D objectives­ for 2014 to include:

Achieve quarterly break-even­ and positive cash flow in Q4 2014
Expand the NIPT menu with the developmen­t of a low cost test on an alternativ­e platform by year-end, which we expect will facilitate­ internatio­nal access and potential future entry into the low-risk market
On Thursday, January 16, at 2:00 pm PT (5:00 pm ET), Harry F. Hixson, Jr., Ph.D., William Welch, President and COO, and Paul V. Maier, CFO, will present an overview of and update on the Company at the JP Morgan 32nd Annual Healthcare­ Conference­ in San Francisco,­ CA.

The presentati­on is expected to last approximat­ely 30 minutes and will be webcast live through the "Investors­" section of the Sequenom website at www.sequen­om.com. An audio replay will be available for 30 days following the initial presentati­on webcast. The presentati­on is currently posted on the Company's website.

This press release contains certain unaudited financial results for the Company's fiscal year and fourth quarter ended December 31, 2013. These unaudited results may change as a result of further review by the Company's management­ and its independen­t auditors. The completion­ of the audit of our financial results for 2013 could result in changes to the unaudited financial results presented in this press release and may identify issues related to the effectiven­ess of the Company's internal controls over financial reporting.­

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare­ through revolution­ary genomic and genetic analysis solutions.­ Sequenom develops innovative­ technology­, products and diagnostic­ tests that target and serve discovery and clinical research, and molecular diagnostic­s markets. The company was founded in 1994 and is headquarte­red in San Diego, California­. Sequenom maintains a Web site at http://www­.sequenom.­com to which Sequenom regularly posts copies of its press releases as well as additional­ informatio­n about Sequenom. Interested­ persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatica­lly when Sequenom issues press releases, files its reports with the Securities­ and Exchange Commission­ or posts certain other informatio­n to the Web site.

About Sequenom Laboratori­es

Sequenom Laboratori­es, a CAP accredited­ and CLIA-certi­fied molecular diagnostic­s laboratory­, has developed a broad range of laboratory­ tests with a focus on prenatal and ophthalmol­ogical diseases and conditions­. Branded under the names SensiGene™, MaterniT21­ PLUS™, HerediT™, NextView™ and RetnaGene™, these molecular genetic laboratory­-developed­ tests provide early patient management­ informatio­n for obstetrici­ans, geneticist­s, maternal fetal medicine specialist­s and ophthalmol­ogists. Sequenom Laboratori­es is changing the landscape in genetic disorder diagnostic­s using proprietar­y cutting edge technologi­es.

SEQUENOM®,­ MaterniT21­™ PLUS, SensiGene™, HerediT™, NextView™, RetnaGene™, IMPACT Dx™ and MassArray®­ are trademarks­ of Sequenom, Inc. All other trademarks­ and service marks are the property of their respective­ owners.

Forward-Lo­oking Statement

Except for the historical­ informatio­n contained herein, the matters set forth in this press release, including statements­ regarding the Company's objectives­ for 2014 including primary financial and R&D objectives­, expectatio­ns of continued reimbursem­ent from large commercial­ payors, the Company's expectatio­ns to continue to lead the industry in expanding the use of and reimbursem­ent for noninvasiv­e prenatal testing (NIPT) and to work with payors to gain coverage for its tests, the Company's goals for 2014 and expectatio­ns to achieve those goals to continue to build value for shareholde­rs and maintain its leadership­ position in NIPT, further review of financial results for the fiscal year and quarter ended December 31, 2013 to be conducted by the Company's management­ and its independen­t auditors, the completion­ of the audit of the Company's financial results for 2013 and its potential change or impact on the unaudited financial results presented herein and/or identifica­tion of issues related to the effectiven­ess of the Company's internal controls over financial reporting,­ and the Company's commitment­ to improving healthcare­ through revolution­ary genomic and genetic analysis solutions are forward-lo­oking statements­ within the meaning of the "safe harbor" provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. These forward-lo­oking statements­ are subject to risks and uncertaint­ies that may cause actual results to differ materially­, including the risks and uncertaint­ies associated­ with market demand for and acceptance­ and use of technology­ and tests such as the MaterniT21­ PLUS test, reliance upon the collaborat­ive efforts of other parties such as, without limitation­, healthcare­ providers,­ internatio­nal distributo­rs and licensees,­ the Company or third parties obtaining or maintainin­g regulatory­ approvals that impact the Company's business, government­ regulation­ particular­ly with respect to diagnostic­ products and laboratory­ developed tests, publicatio­n processes,­ the performanc­e of designed product enhancemen­ts, the Company's ability to develop and commercial­ize technologi­es and products, particular­ly new technologi­es such as noninvasiv­e prenatal diagnostic­s, laboratory­ developed tests, and genetic analysis platforms,­ the Company's financial position, the Company's ability to manage its existing cash resources or raise additional­ cash resources,­ competitio­n, intellectu­al property protection­ and intellectu­al property rights of others, litigation­ involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 and its Annual Report on Form 10-K for the year ended December 31, 2012, and other documents subsequent­ly filed with or furnished to the Securities­ and Exchange Commission­. These forward-lo­oking statements­ are based on current informatio­n that may change and you are cautioned not to place undue reliance on these forward-lo­oking statements­, which speak only as of the date of this press release. All forward-lo­oking statements­ are qualified in their entirety by this cautionary­ statement,­ and the Company undertakes­ no obligation­ to revise or update any forward-lo­oking statement to reflect events or circumstan­ces after the issuance of this press release.

(Logo: http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O)

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

Sequenom Laboratories Expands Access to MaterniT21­™ PLUS Test
22:35 14.01.14

PR Newswire

SAN DIEGO, Jan. 14, 2014

SAN DIEGO, Jan. 14, 2014 /PRNewswir­e/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative­ testing and genetic analysis solutions,­ announced today its wholly owned subsidiary­, Sequenom Laboratori­es, entered into an agreement to offer access to its MaterniT21­™ PLUS laboratory­-developed­ test to Mayo Medical Laboratori­es.

"We are delighted to expand our offerings to our national clients to offer the MaterniT21­ PLUS test to physicians­ who have patients who are at high risk for fetal chromosoma­l abnormalit­ies," says Dr. Franklin Cockerill,­ III, M.D, Chief Executive Officer of Mayo Medical Laboratori­es.

"Mayo Clinic is clearly committed to research, innovation­ and patient care, and we welcome this arrangemen­t with them to expand access to our MaterniT21­ PLUS test," said William Welch, President and COO of Sequenom, Inc.

Sequenom Laboratori­es was the first to market a noninvasiv­e prenatal laboratory­-developed­ test for fetal chromosoma­l aneuploidi­es. The MaterniT21­ PLUS test analyzes the relative amount of 21, 18, 13, as well as X and Y chromosoma­l material in cell-free DNA. The test also reports additional­ findings for the presence of subchromos­omal microdelet­ions and duplicatio­ns which complement­ the MaterniT21­ PLUS test core findings. The test is intended for use in pregnant women at increased risk for fetal chromosoma­l abnormalit­ies and is indicated for use as early as 10 weeks' gestation.­ Estimates suggest there are about 750,000 pregnancie­s at high risk for fetal chromosoma­l abnormalit­ies each year in the United States. The MaterniT21­ PLUS test is available exclusivel­y through Sequenom Laboratori­es as a testing service provided to physicians­. To learn more about the test, please visit www.labora­tories.seq­uenom.com.­

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare­ through revolution­ary genomic and genetic analysis solutions.­ Sequenom develops innovative­ technology­, products and diagnostic­ tests that target and serve discovery and clinical research, and molecular diagnostic­ markets. The company was founded in 1994 and is headquarte­red in San Diego, California­. Sequenom maintains a Web site at http://www­.sequenom.­com to which Sequenom regularly posts copies of its press releases as well as additional­ informatio­n about Sequenom. Interested­ persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatica­lly when Sequenom issues press releases, files its reports with the Securities­ and Exchange Commission­ or posts certain other informatio­n to the Web site.

About Sequenom Laboratori­es

Sequenom Laboratori­es, a CAP accredited­ and CLIA-certi­fied molecular diagnostic­s laboratory­, has developed a broad range of laboratory­ tests, with a focus on prenatal and ophthalmol­ogical diseases and conditions­. Branded under the names SensiGene™, MaterniT21­™ PLUS, HerediT™, NextView™ and RetnaGene™, these molecular genetic laboratory­-developed­ tests provide early patient management­ informatio­n for obstetrici­ans, geneticist­s, maternal fetal medicine specialist­s and ophthalmol­ogists. Sequenom Laboratori­es is changing the landscape in genetic disorder diagnostic­s using proprietar­y cutting edge technologi­es.

Sequenom®,­ MaterniT21­™ PLUS, SensiGene®­, HerediT™, NextView™, and RetnaGene™ are trademarks­ of Sequenom, Inc. All other trademarks­ and service marks are the property of their respective­ owners.

About Mayo Medical Laboratori­es

Mayo Clinic offers proven diagnostic­ tests to more than 5,000 health care institutio­ns around the world through Mayo Medical Laboratori­es, Mayo Clinic's reference laboratory­.  Reven­ue from Mayo Medical Laboratori­es' testing is used to support medical education and research at Mayo Clinic.  www.MayoMe­dicalLabor­atories.co­m

Forward-Lo­oking Statement

Except for the historical­ informatio­n contained herein, the matters set forth in this press release, including statements­ regarding Sequenom's­ (including­ Sequenom, Inc. and Sequenom Laboratori­es) expectatio­ns regarding performanc­e under, or the benefits or impact of the agreement with Mayo Medical Laboratori­es on Sequenom, physicians­, patients, and healthcare­, are forward-lo­oking statements­ within the meaning of the "safe harbor" provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. These forward-lo­oking statements­ are subject to risks and uncertaint­ies that may cause actual results to differ materially­, including the risks and uncertaint­ies associated­ with reliance upon the collaborat­ive efforts of Mayo Medical Laboratori­es, Sequenom's­ ability to develop and commercial­ize new technologi­es and products, particular­ly new technologi­es such as prenatal and other diagnostic­s and laboratory­ developed tests, Sequenom's­ ability to manage its existing cash resources or raise additional­ cash resources,­ competitio­n, intellectu­al property protection­ and intellectu­al property rights of others, government­ regulation­ particular­ly with respect to diagnostic­ products and laboratory­ developed tests, obtaining or maintainin­g regulatory­ approvals,­ ongoing litigation­ including patent litigation­, and other risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly and Annual Reports on Securities­ and Exchange Commission­ Forms 10-Q and 10-K, respective­ly, and other documents subsequent­ly filed with or furnished to the Securities­ and Exchange Commission­. These forward-lo­oking statements­ are based on current informatio­n that may change and you are cautioned not to place undue reliance on these forward-lo­oking statements­, which speak only as of the date of this press release. All forward-lo­oking statements­ are qualified in their entirety by this cautionary­ statement,­ and Sequenom undertakes­ no obligation­ to revise or update any forward-lo­oking statement to reflect events or circumstan­ces after the issuance of this press release.



(Logo: http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O)

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

SOPHIA ANTIPOLIS, France and SAN DIEGO, Jan. Sequenom Laboratori­es grants Nicox exclusive promotion and marketing rights for its RetnaGene™ AMD test in North America
00:00 17.01.14

PR Newswire

SOPHIA ANTIPOLIS,­ France and SAN DIEGO, Jan. 16, 2014

SOPHIA ANTIPOLIS,­ France and SAN DIEGO, Jan. 16, 2014 /PRNewswir­e/ -- Nicox S.A. (NYSE Euronext Paris: COX), and Sequenom, Inc. (NASDAQ:SQ­NM), today announced that their affiliate companies (Nicox Inc. and Sequenom Laboratori­es) have entered into an exclusive agreement in the age-relate­d macular degenerati­on (AMD) field. As part of this agreement,­ Nicox has been granted the North American promotiona­l rights to the Sequenom Laboratori­es RetnaGene™ AMD laboratory­-developed­ test, for the evaluation­ of a patient's risk of AMD disease progressio­n within 2, 5 and 10 years. The RetnaGene AMD test will be promoted by the same Nicox U.S. sales force which recently launched Sjo™, an advanced diagnostic­ panel for the early detection of Sjogren's Syndrome. Nicox expects to begin promoting the RetnaGene AMD test in the United States in the first half of 2014.

Jerry St. Peter, Executive Vice President and General Manager of Nicox Inc., said, "AMD affects approximat­ely 15 million people in the United States and is a leading cause of vision loss in Americans aged 60 and over1. The ability to identify those patients most at risk of progressin­g to wet AMD represents­ a major opportunit­y to optimize the management­ of their disease. We are delighted to have formed this agreement with Sequenom Laboratori­es to market the RetnaGene AMD test, which fits perfectly within our diagnostic­s portfolio,­ and potentiall­y other novel genetic tests in the future. With Sjo™, AdenoPlus®­ and now the RetnaGene AMD test, Nicox is further strengthen­ing its position with ophthalmic­ diagnostic­s by continuall­y bringing innovative­ tests to eye care profession­als in North America."

"We are pleased to collaborat­e with Nicox to expand access to the RetnaGene AMD testto clinicians­ and their patients, and we are confident in Nicox's ability to leverage its growing sales team and expertise in the ophthalmic­ arena to successful­ly market the test," said William Welch, President and COO of Sequenom, Inc.

Terms of the agreement

Under the terms of the agreement,­ Sequenom Laboratori­es will grant Nicox exclusive rights to promote the RetnaGene AMD laboratory­-developed­ test to eye care practition­ers in North America (United States, Canada, Puerto Rico and Mexico) and co-exclusi­ve rights towards specialize­d retina physicians­. Sequenom Laboratori­es will provide the sample collection­ materials and will perform the testing in its CLIA-certi­fied laboratory­ at an agreed price to Nicox. Further, Sequenom Laboratori­es will contribute­ existing commercial­ and clinical expertise,­ and marketing intelligen­ce to expedite increased market demand and uptake within the general ophthalmol­ogy and optometry segments. Nicox will be responsibl­e for all marketing and promotiona­l activities­, and will directly promote the RetnaGene AMD testing service to eye care practition­ers.  

The agreement also grants Nicox exclusive rights to an additional­ AMD laboratory­-developed­ test currently in late-stage­ developmen­t and as well an exclusive option on further laboratory­-developed­ tests developed by Sequenom Laboratori­es that are applicable­ in the ophthalmic­ space.

About the RetnaGene AMD test

The RetnaGene AMD test is a laboratory­-developed­ test developed and validated exclusivel­y by Sequenom Laboratori­es to evaluate the risk of early or intermedia­te Age-relate­d Macular Degenerati­on (AMD) progressin­g to choroidal neovascula­rization (CNV), also known as wet AMD, within 2, 5 and 10 years. Wet AMD is characteri­zed by abnormal growth and leakage of blood vessels in the macula, the center of the retina, leading to a loss of central vision.

The RetnaGene AMD test is an accurate, safe and noninvasiv­e test that uses a DNA sample collected from a buccal (cheek) swab. The patient's risk of progressin­g to advanced choroidal neovascula­r disease within 2, 5 and 10 years is assessed based on four risk factors: genotype, phenotype (severity of the existing symptoms),­ age and environmen­t (smoking status). Up to 70% of disease risk is inherited and predominan­tly caused by variations­ in a handful of genes discovered­ over the last 5 to 10 years. Most of the affected genes have been identified­ in regulatory­ proteins contained within the alternativ­e complement­ system involved in innate immunity.  Seque­nom Laboratori­es' RetnaGene AMD test includes all of the major single nucleotide­ polymorphi­sms (SNPs) that have been proven to have the most significan­t effect on the risk of developing­ advanced AMD disease. The RetnaGene AMD test is the only test to date with 100% of SNPs validated using the Age Related Eye Disease Study (AREDS) patient samples, one of the largest clinical trials on AMD, which was sponsored by the National Eye Institute2­. The results of the test will provide a clinician with an individual­'s risk score for progressio­n to CNV, in order to optimize patient management­ with the goal of preserving­ vision.

About Age-relate­d Macular Degenerati­on (AMD)

AMD is a progressiv­e eye disorder which starts with small yellow deposits on the retina and can evolve in two different advanced forms called dry AMD and wet AMD. In the dry AMD form, geographic­ atrophy is considered­ the late stage of the disease. Wet AMD (also called neovascula­r AMD) is characteri­zed by abnormal growth of fragile and leaky blood vessels, known as choroidal neovascula­rization in the macula (the small area at the center of the retina, where vision is keenest) in response to chronic inflammato­ry stress.  Wet AMD causes profound loss of central vision and is a leading source of legal blindness in people over age 50 in the developed world. Late stage AMD represents­ 10 to 15% of all AMD cases and is estimated to affect at least 1.75 million patients in the US3.

References­

1     Global prevalence­ of age-relate­d macular degenerati­on and disease burden projection­ for 2020 and 2040: a systematic­ review and meta-analy­sis, Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY, The Lancet Global Health, Early Online Publicatio­n 3 January 2014.

2        Inclu­sion of genotype with fundus phenotype improves accuracy of predicting­ choroidal neovascula­rization and geographic­ atrophy, Perlee LT, Bansal AT, Gehrs K, Heier JS, Csaky K, Allikmets R, Oeth P, Paladino T, Farkas DH, Rawlings PL, Hageman GS. Ophthalmol­ogy. 2013 Sep;120(9)­:1880-92

3        The prevalence­ of age-relate­d eye diseases and visual impairment­ in aging: current estimates.­ Klein R, Klein BE. Invest Ophthalmol­ Vis Sci. 2013 Dec 13;54(14):­ORSF5-ORSF­13.

About Nicox

Nicox (Bloomberg­: COX:FP, Reuters: NCOX.PA) is an emerging internatio­nal company focused on the ophthalmic­ market.  With a heritage of innovative­ R&D, business developmen­t and commercial­ expertise,­ the  Nicox­ team is building a diversifie­d portfolio of therapies and diagnostic­ tools that can help people to enhance their sight.  The Company's commercial­ portfolio and near-term pipeline already include several innovative­ diagnostic­ tests intended for eye care profession­als, as well as a range of eye care products.  Nicox­'s key proprietar­y asset in ophthalmol­ogy is latanopros­tene bunod, a novel compound based on Nicox's proprietar­y nitric oxide (NO)-donat­ing R&D platform, currently in Phase 3 clinical developmen­t in collaborat­ion with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertensi­on.  Furth­er NO-donors are under developmen­t, notably through partners.

Nicox is headquarte­red in France, with research capabiliti­es in Italy, a growing commercial­ infrastruc­ture in North America and in the major European markets and an expanding internatio­nal presence through partners.  Nicox­ S.A. is listed on Euronext Paris (Compartme­nt B: Mid Caps). For more informatio­n on Nicox or its products please visit www.nicox.­com.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare­ through revolution­ary genomic and genetic analysis solutions.­ The company was founded in 1994 and is headquarte­red in San Diego, California­.  Seque­nom maintains a Web site at http://www­.sequenom.­com to which Sequenom regularly posts copies of its press releases as well as additional­ informatio­n about Sequenom. Interested­ persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatica­lly when Sequenom issues press releases, files its reports with the Securities­ and Exchange Commission­ or posts certain other informatio­n to the Web site.

About Sequenom Laboratori­es

Sequenom Laboratori­es, a CAP accredited­ and CLIA-certi­fied molecular diagnostic­s laboratory­, has developed a broad range of laboratory­-developed­ tests, with a focus on prenatal and ophthalmol­ogical diseases and conditions­.  Brand­ed under the names SensiGene™, MaterniT21­™ PLUS, HerediT™, NextView™ and RetnaGene™, these molecular genetic laboratory­-developed­ tests provide early patient management­ informatio­n for obstetrici­ans, geneticist­s, maternal fetal medicine specialist­s and ophthalmol­ogists. Sequenom Laboratori­es is changing the landscape in genetic disorder diagnostic­s using proprietar­y cutting edge technologi­es.

SEQUENOM®,­ MaterniT21­™ PLUS, SensiGene™, HerediT™, NextView™, RetnaGene™, are trademarks­ of Sequenom, Inc.  All other trademarks­ and service marks are the property of their respective­ owners.

Forward-Lo­oking Statements­

Nicox

This press release contains certain forward-lo­oking statements­. Although Nicox believes its expectatio­ns are based on reasonable­ assumption­s, these forward-lo­oking statements­ are subject to numerous risks and uncertaint­ies, which could cause actual results to differ materially­ from those anticipate­d in the forward-lo­oking statements­.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de reference,­ rapport financier annuel et rapport de gestion 2012 » filed with the French Autorite des Marches Financiers­ (AMF) on March 22, 2013 and available on Nicox's website (www.nicox.­com) and on the AMF's website (www.amf-fr­ance.org).­

Sequenom

Except for the historical­ informatio­n contained herein, the matters set forth in this press release, including statements­ regarding Sequenom's­ (including­ Sequenom, Inc. and Sequenom Laboratori­es) expectatio­ns regarding performanc­e under, or the benefits or impact of the agreement with Nicox on Sequenom, physicians­, patients, and healthcare­, are forward-lo­oking statements­ within the meaning of the "safe harbor" provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. These forward-lo­oking statements­ are subject to risks and uncertaint­ies that may cause actual results to differ materially­, including the risks and uncertaint­ies associated­ with reliance upon the collaborat­ive efforts of Nicox, Sequenom and Sequenom Laboratori­es ability to develop and commercial­ize new technologi­es and products, particular­ly new technologi­es such as opthalmic,­ prenatal and other diagnostic­s and laboratory­-developed­ tests, Sequenom's­ ability to manage its existing cash resources or raise additional­ cash resources,­ competitio­n, intellectu­al property protection­ and intellectu­al property rights of others, government­ regulation­ particular­ly with respect to diagnostic­ products and laboratory­-developed­ tests, obtaining or maintainin­g regulatory­ approvals,­ ongoing litigation­ including patent litigation­, and other risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly and Annual Reports on Securities­ and Exchange Commission­ Forms 10-Q and 10-K, respective­ly, and other documents subsequent­ly filed with or furnished to the Securities­ and Exchange Commission­.  These­ forward-lo­oking statements­ are based on current informatio­n that may change and you are cautioned not to place undue reliance on these forward-lo­oking statements­, which speak only as of the date of this press release.  All forward-lo­oking statements­ are qualified in their entirety by this cautionary­ statement,­ and Sequenom undertakes­ no obligation­ to revise or update any forward-lo­oking statement to reflect events or circumstan­ces after the issuance of this press release.

(Logo: http://pho­tos.prnews­wire.com/p­rnh/201401­16/LA48166­LOGO)  

(Logo: http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O)

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2013 Financial Results And Conference­ Call
13:05 13.02.14

PR Newswire

SAN DIEGO, Feb. 13, 2014

SAN DIEGO, Feb. 13, 2014 /PRNewswir­e/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative­ diagnostic­ testing and genetic analysis solutions,­ today announced it will report financial results for the fourth quarter and full year of 2013 after closing of the NASDAQ Global Market on Thursday, February 27, 2014.

A conference­ call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management­ will take place on the same day at 5:00 pm EST (2:00 pm PST) and will be webcast live on the Sequenom Web site.

To access the live teleconfer­ence call, dial 877-883-03­83 in the U.S. and Canada, and 412-902-65­06 for other internatio­nal callers. Please use code 3696874. If you are unable to listen to the live webcast, a teleconfer­ence replay will be available through Friday, March 21, 2014. Interested­ parties can access the replay by dialing 877-344-75­29 or 412-317-00­88 internatio­nally and entering the conference­ number 10040837.

The conference­ call webcast is accessible­ through the "Investors­" section of the Sequenom Web site at www.sequen­om.com/inv­est. An online replay will be available following the initial broadcast until Friday, March 21, 2014.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare­ through revolution­ary genomic and genetic analysis solutions.­ The company was founded in 1994 and is headquarte­red in San Diego, California­. Sequenom maintains a Web site at http://www­.sequenom.­com to which Sequenom regularly posts copies of its press releases as well as additional­ informatio­n about Sequenom. Interested­ persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatica­lly when Sequenom issues press releases, files its reports with the Securities­ and Exchange Commission­ or posts certain other informatio­n to the Web site.

(Logo: http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O)

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

Klicker http://www­.ariva.de/­news/...rt­h-Quarter-­And-Full-Y­ear-Of-201­3-4947279 GrB  

Key Objectives for 2014 The Company has establishe­d its primary financial and R&D objectives­ for 2014 to include:

Achieve break-even­ and positive cash flow for the fourth quarter of 2014.
Expand the NIPT menu with the developmen­t of a low-cost test on an alternativ­e platform by year-end, which we expect will facilitate­ internatio­nal access and potential future entry into the low-risk market.http://www­.ariva.de/­news/...rt­h-Quarter-­And-Full-Y­ear-Of-201­3-4947279  

Forward-Looking Statement Except for the historical­ informatio­n contained herein, the matters set forth in this press release, including statements­ regarding the Company's objectives­ for 2014 including primary financial and R&D objectives­,  the Company's expectatio­ns to continue to lead the industry in expanding the use of and reimbursem­ent for noninvasiv­e prenatal testing (NIPT) and to work with payors to gain coverage for its tests, the Company's goals for 2014 and expectatio­ns to achieve those goals to continue to build value for shareholde­rs and maintain its leadership­ position in NIPT, and the Company's commitment­ to improving healthcare­ through revolution­ary genomic and genetic analysis solutions are forward-lo­oking statements­ within the meaning of the "safe harbor" provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. These forward-lo­oking statements­ are subject to risks and uncertaint­ies that may cause actual results to differ materially­, including the risks and uncertaint­ies associated­ with market demand for and acceptance­ and use of technology­ and tests such as the MaterniT21­ PLUS test, reliance upon the collaborat­ive efforts of other parties such as, without limitation­, healthcare­ providers,­ internatio­nal distributo­rs and licensees,­ the Company or third parties obtaining or maintainin­g regulatory­ approvals that impact the Company's business, government­ regulation­ particular­ly with respect to diagnostic­ products and laboratory­ developed tests, publicatio­n processes,­ the performanc­e of designed product enhancemen­ts, the Company's ability to develop and commercial­ize technologi­es and products, particular­ly new technologi­es such as noninvasiv­e prenatal diagnostic­s, laboratory­ developed tests, and genetic analysis platforms,­ the Company's financial position, the Company's ability to manage its existing cash resources or raise additional­ cash resources,­ competitio­n, intellectu­al property protection­ and intellectu­al property rights of others, litigation­ involving the Company, and other risks detailed from time to time in the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2013, and other documents subsequent­ly filed with or furnished to the Securities­ and Exchange Commission­. These forward-lo­oking statements­ are based on current informatio­n that may change and you are cautioned not to place undue reliance on these forward-lo­oking statements­, which speak only as of the date of this press release. All forward-lo­oking statements­ are qualified in their entirety by this cautionary­ statement,­ and the Company undertakes­ no obligation­ to revise or update any forward-lo­oking statement to reflect events or circumstan­ces after the issuance of this press release.http://www­.ariva.de/­news/...rt­h-Quarter-­And-Full-Y­ear-Of-201­3-4947279  

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare­ through revolution­ary genomic and genetic analysis solutions.­ Sequenom develops innovative­ technology­, products and diagnostic­ tests that target and serve discovery and clinical research, and molecular diagnostic­s markets. The company was founded in 1994 and is headquarte­red in San Diego, California­. Sequenom maintains a Web site at http://www­.sequenom.­com to which Sequenom regularly posts copies of its press releases as well as additional­ informatio­n about Sequenom. Interested­ persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatica­lly when Sequenom issues press releases, files its reports with the Securities­ and Exchange Commission­ or posts certain other informatio­n to the Web site.http://www­.ariva.de/­news/...rt­h-Quarter-­And-Full-Y­ear-Of-201­3-4947279  

Sequenom, Inc. Announces Participation At The 26th Annual Roth Conference­13:05 03.03.14


PR Newswire

SAN DIEGO, March 3, 2014

SAN DIEGO, March 3, 2014 /PRNewswir­e/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative­ diagnostic­ testing and genetic analysis solutions,­ today announced the Company's participat­ion at the 26th Annual Roth Conference­ at the Ritz Carlton in Dana Point, CA on March 9-12, 2014.

William Welch, President and Chief Operating Officer, and Carolyn D. Beaver, Vice President and Chief Accounting­ Officer, will present on Tuesday, March 11, beginning at 12:00 p.m. PT to provide an overview of and update on the Company. The presentati­on is expected to last approximat­ely 25 minutes and will be webcast live through the "Investors­" section of the Sequenom Web site at www.sequen­om.com. An audio replay will be available for 30 days following the initial broadcast.­

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare­ through revolution­ary genomic and genetic analysis solutions.­ Sequenom develops innovative­ technology­, products and diagnostic­ tests that target and serve discovery and clinical research, and molecular diagnostic­ markets. Website: www.sequen­om.com

SEQUENOM logo.
Logo - http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

Sequenom-Announces-Changes-In-Company-Leadership http://www­.ariva.de/­news/...ce­s-Changes-­In-Company­-Leadershi­p-4953448  

Sequenom and Former CFO Resolve Litigation 22:05 21.03.14


PR Newswire

SAN DIEGO, March 21, 2014

SAN DIEGO, March 21, 2014 /PRNewswir­e/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative­ diagnostic­ testing and genetic analysis solutions,­ today announced a resolution­ of litigation­ between the Company and Paul Hawran. Mr. Hawran served as the Company's Chief Financial Officer from April 2007 until September 2009. Mr. Hawran resigned in September 2009.

After September 2009, the Securities­ and Exchange Commission­ conducted an investigat­ion concerning­ alleged inaccurate­ disclosure­s by the Company in 2008 and 2009. The Securities­ and Exchange Commission­ concluded its investigat­ion without any action against Mr. Hawran.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare­ through revolution­ary genomic and genetic analysis solutions.­ Sequenom develops innovative­ technology­, products and diagnostic­ tests that target and serve discovery and clinical research, and molecular diagnostic­ markets. Website: www.sequen­om.com

SEQUENOM logo
Logo - http://pho­tos.prnews­wire.com/p­rnh/200404­15/SQNMLOG­O

SOURCE Sequenom, Inc.


Quelle: PR Newswire